Dr. Lee-may Chen, MD
Claim this profileUCSF Medical Center-Mission Bay
Studies Serous Cystadenocarcinoma
Studies Cancer
6 reported clinical trials
11 drugs studied
Area of expertise
1Serous Cystadenocarcinoma
Stage III
Stage IV
Stage II
2Cancer
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Lee-may Chen, MD is currently running
Letrozole +/- Chemotherapy
for Ovarian Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
Recruiting2 awards Phase 318 criteria
Surgical Procedures
for Reducing Ovarian Cancer Risk
This study evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Recruiting1 award N/A
More about Lee-may Chen, MD
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Lee-may Chen, MD has experience with
- Letrozole
- Pembrolizumab
- Ribociclib
- ZN-c3
- Paclitaxel, Carboplatin
- Carboplatin
Breakdown of trials Lee-may Chen, MD has run
Serous Cystadenocarcinoma
Cancer
Ovarian Cancer
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lee-may Chen, MD specialize in?
Lee-may Chen, MD focuses on Serous Cystadenocarcinoma and Cancer. In particular, much of their work with Serous Cystadenocarcinoma has involved Stage III patients, or patients who are Stage IV.
Is Lee-may Chen, MD currently recruiting for clinical trials?
Yes, Lee-may Chen, MD is currently recruiting for 2 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that Lee-may Chen, MD has studied deeply?
Yes, Lee-may Chen, MD has studied treatments such as Letrozole, Pembrolizumab, Ribociclib.
What is the best way to schedule an appointment with Lee-may Chen, MD?
Apply for one of the trials that Lee-may Chen, MD is conducting.
What is the office address of Lee-may Chen, MD?
The office of Lee-may Chen, MD is located at: UCSF Medical Center-Mission Bay, San Francisco, California 94158 United States. This is the address for their practice at the UCSF Medical Center-Mission Bay.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.